References
Palmer JR, Rosenberg L, Strom BL, et al. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 1992; 3: 547–54.
Skegg DCG. Potential for bias in case-control studies of oral contraceptives and breast cancer. Am J Epidemiol 1988; 127: 205–12.
Fox MS. On the diagnosis and treatment of breast cancer. JAMA 1979; 241: 489–94.
Sheldon CA, Williams RD, Fraley EE. Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. J Urol 1980; 124: 626–31.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–16.
Horn-Ross PL, Holly EA, Brown SR, Aston DA. Temporal trends in the incidence of cutaneous malignant melanoma among Caucasians in the San Francisco-Oakland MSA. Cancer Causes Control 1991; 2: 299–305.
Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325: 171–82.
McGovern VJ. Spontaneous regression of melanoma. Pathology 1975; 7: 91–9.
Barnhill RL, Kiryu H, Sober AJ, Mihm MC. Frequency of dysplastic nevi among nevomelanocytic lesions submitted for histopathologic examination. Time trends over a 37-year period. Arch Dermatol 1990; 126: 463–5.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Palmer, J.R., Rosenberg, L. & Shapiro, S. The authors' reply. Cancer Causes Control 4, 396–397 (1993). https://doi.org/10.1007/BF00051345
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00051345